Fermentas

US patents awarded to University of California, Hospital for Sick Children, Thermo Fisher, Fujifilm, Abbott, and Novartis.

The deal is expected to bolster Thermo's capabilities in PCR and quantitative real-time PCR.

The acquisition will add reagents for nucleic acid and protein purification, restriction and modifying enzymes, and other life science research and diagnostic tools to Thermo's Analytical Technologies portfolio.

When considering Thermo's planned acquisition of molecular biology tool shop Fermentas, its acquisition earlier this year of Finnish PCR firm Finnzymes, and recent product launches, it appears as if the company plans to make a run at disease diagnostics, food testing, and other PCR-based testing markets.

Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."

Based in Ontario with principal operations in Lithuania, Fermentas offers reagents for nucleic acid and protein purification, restriction and modifying enzymes, and various PCR products.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.